| Literature DB >> 12165396 |
Luisa Rossi1, Rosanna Squitti, Patrizio Pasqualetti, Eliana Marchese, Emanuele Cassetta, Elisabetta Forastiere, Giuseppe Rotilio, Paolo M Rossini, Alessandro Finazzi-Agró.
Abstract
Copper, zinc superoxide dismutase (Cu, Zn SOD) activity was measured in red blood cells (RBC) of 32 patients affected by Alzheimer's disease (AD), eight other AD patients treated with the copper-chelating agent D-penicillamine, 13 first-degree relatives and 22 controls. All AD patients enrolled in our study showed a higher level of Cu, Zn SOD activity early in the disease. No correlation between apolipoprotein E genotype and SOD activity was found in AD patients. D-penicillamine treatment of AD patients for 24 weeks lowered the enzyme activity even below the control value. These results support the hypothesis that a higher level of Cu, Zn SOD activity in RBC can be an early diagnostic peripheral marker of this disease and a sensor to monitor treatments with copper-chelating drugs. Copyright 2002 Elsevier Science Ireland Ltd.Entities:
Mesh：
Substances：
Year: 2002 PMID： 12165396 DOI： 10.1016/s0304-3940(02)00599-2
Source DB: PubMed Journal: Neurosci Lett ISSN： 0304-3940 Impact factor: 3.046